Kiora Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company, which is engaged in developing and commercializing therapies for the treatment of retinal diseases. The Company is engaged in developing KIO-301, a vision-restoring small molecule that acts as a photoswitch specifically created to restore vision in patients with inherited and age-related degenerative retinal diseases, including retinitis pigmentosa (RP). It is also developing KIO-104 for the treatment of retinal inflammatory diseases, including Diabetic Macular Edema (DME) and Posterior Non-Infectious Uveitis, a rare T cell-mediated, intraocular inflammatory disease. KIO-104 is a non-steroidal small-molecule inhibitor of dihydroorotate dehydrogenase (DHODH) formulated for intravitreal delivery and is ideally suited to suppressing overactive T-cell activity to treat the underlying inflammation. KIO-101 focuses on treating the ocular manifestation of patients with autoimmune diseases.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
30/10/26	US$1.560	-11.36%	100,691
29/10/26	US$1.760	-25.42%	490,621
28/10/26	US$2.360	+2.61%	30,278
27/10/26	US$2.300	+4.07%	16,522
26/10/26	US$2.210	-3.49%	24,984

Delayed Quote Nasdaq

More quotes

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

1.560USD

Average target price

12.00USD

Spread / Average Target

+669.23%

Consensus

EPS Estimates

Evolution of Analysts' Estimates - EPS - Kiora Pharmaceuticals, Inc.

Revisions to estimates

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Kiora Pharmaceuticals, Inc.

Company calendar

Market Closed - Nasdaq 20:00:00 30/10/2026 GMT			5-day change	1st Jan Change
1.560 ^USD	-11.36%		-31.88%	-20.81%

09-08	Kiora Pharmaceuticals, Inc. Appoints Keith Lane as Executive Vice President, Head of Clinical Development and Regulatory Affairs, Effective September 1, 2026	CI
08-19	Kiora Pharmaceuticals, Inc. Licenses South Korean Ophthalmic Development And Commercialization Rights For KIO-301 To Chong Kun Dang Pharmaceutical Corporation	CI

Market Cap	9.93M 8.89M 8.18M 7.41M 13.85M 943M 14.11M 97.52M 39.15M 496M 37.25M 36.46M 1.56B	P/E 2026 *	-0.93x	P/E 2027 *	-1.11x
Enterprise Value	9.93M 8.89M 8.18M 7.41M 13.85M 943M 14.11M 97.52M 39.15M 496M 37.25M 36.46M 1.56B	EV / Sales 2026 *	-	EV / Sales 2027 *	-
Free-Float	91.09%	Yield 2026 *	-	Yield 2027 *	-

Markets		Quality
Nasdaq	KPRX	Delayed
CBOE	KPRX	Real-time

09-08	Kiora Pharmaceuticals, Inc. Appoints Keith Lane as Executive Vice President, Head of Clinical Development and Regulatory Affairs, Effective September 1, 2026	CI
08-19	Kiora Pharmaceuticals, Inc. Licenses South Korean Ophthalmic Development And Commercialization Rights For KIO-301 To Chong Kun Dang Pharmaceutical Corporation	CI
08-07	Kiora Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
05-08	Kiora Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-09	Plus Therapeutics, Inc. Appoints Eric J. Daniels as Chief Development Officer, Effective April 20, 2026	CI
04-07	Kiora Pharmaceuticals Inc - Enters securities purchase agreement on April 3, 2026 - SEC filing	RE
04-05	Kiora Pharmaceuticals, Inc. announced that it has received $5.000001 million in funding from ADAR1 Capital Management, LLC and another investor	CI
04-02	Kiora Pharmaceuticals, Inc. announced that it expects to receive $5.000001 million in funding from ADAR1 Capital Management, LLC and another investor	CI
04-02	Kiora Pharmaceuticals, Inc. Announces Resignation of Eric J. Daniels, M.D., MBA as Chief Development Officer, Effective April 17, 2026	CI
03-25	Kiora Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
11-07	Kiora Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
30/10/25	Kiora Pharmaceuticals Joins RARE-X Vision Consortium Promoting Collaboration and Development of New Treatments for Rare Ocular Disorders	CI
15/09/25	Kiora Pharmaceuticals files for mixed shelf offering of up to $100 million- SEC filing	RE

Kiora Pharmaceuticals, Inc. Share Price

Stocks

KPRX

US49721T5074

Biotechnology & Medical Research

Valuation: Kiora Pharmaceuticals, Inc.

Chart: Kiora Pharmaceuticals, Inc.

Latest news: Kiora Pharmaceuticals, Inc.

Analysts' recommendations: Kiora Pharmaceuticals, Inc.

Press Releases: Kiora Pharmaceuticals, Inc.

News in other languages: Kiora Pharmaceuticals, Inc.

Quotes and Performance

Price Extremes

Managers and Directors: Kiora Pharmaceuticals, Inc.

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Analysts' Consensus

Quarterly revenue - Rate of surprise

09/02/24	HC Wainwright Adjusts Price Target on Kiora Pharmaceuticals to $2 From $3.50, Maintains Buy Rating	MT
06/11/23	HC Wainwright Adjusts Kiora Pharmaceuticals' Price Target to $3.50 From $2, Keeps Buy Rating	MT
14/08/23	HC Wainwright Adjusts Price Target on Kiora Pharmaceuticals to $2 From $7, Keeps Buy Rating	MT
12/05/23	HC Wainwright Raises Kiora Pharmaceuticals' Price Target to $7 From $6, Maintains Buy Rating	MT
09/02/23	Maxim Upgrades Kiora Pharmaceuticals to Buy From Hold, Price Target is $12	MT

10-29	Kiora Pharmaceuticals In-Licenses Late-Stage, Oral Neuroprotective Calpain Inhibitor for Central Retinal Artery Occlusion (CRAO) with Planned Expansion into NAION; Asset Completed Phase 3 Clinical Trial in CRAO in Japan	NE
09-08	Kiora Pharmaceuticals Appoints Keith J. Lane as Executive Vice President of Global Clinical Development and Regulatory Affairs	NE
08-19	Kiora Pharmaceuticals Licenses South Korean Ophthalmic Development and Commercialization Rights for KIO-301 to Chong Kun Dang Pharmaceutical Corporation	NE
08-07	Kiora Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update	NE
07-02	Kiora Pharmaceuticals to Participate in Piper Sandler Virtual Ophthalmology Symposium	NE

1 day	-11.36%
1 week	-31.88%
1 month	-39.06%
3 months	-39.06%
6 months	-33.62%
Current year	-20.81%

1 week	1.55	2.57
1 month	1.55	2.62
Current year	1.55	2.91
1 year	1.55	2.91
3 years	1.55	8.98
5 years	1.55	765.43
10 years	1.55	21,060.02

Manager	Title	Age	Since
Brian Strem CEO	Chief Executive Officer	46	25/07/2021
Melissa Tosca DFI	Director of Finance/CFO	46	30/06/2024
Stefan Sperl COO	Chief Operating Officer	-	-

Director	Title	Age	Since
Praveen Tyle CHM	Chairman	66	20/09/2023
Aron Shapiro BRD	Director/Board Member	48	31/03/2021
Brian Strem BRD	Director/Board Member	46	25/07/2021

Date	Insider	Type	Main position	Quantity	% Market Cap.
17/09/26	Keith Lane	Free	General Counsel	55,000	1.2431%
01/07/26	Melissa Tosca	Tax	Chief Financial Officer	-911	0.0206%
01/07/26	Brian Strem	Tax	Chief Executive Officer	-1,869	0.0422%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
KIORA PHARMACEUTICALS, INC.	-11.36%	-31.88%	-32.47%	-70.62%	9.93M
WUXI APPTEC CO., LTD.	-0.62%	-1.87%	+42.87%	+64.15%	63.77B
ARGENX SE	+0.35%	+3.20%	+14.40%	+81.76%	56.37B
LONZA GROUP AG	+0.53%	+1.96%	+16.24%	+103.35%	54.62B
IQVIA HOLDINGS INC.	-2.81%	-4.31%	+23.50%	+47.83%	44.06B
BEONE MEDICINES AG	-0.33%	-1.93%	+19.28%	+98.80%	42.11B
REVOLUTION MEDICINES, INC.	+0.55%	+2.31%	+225.14%	+866.21%	41B
GENMAB A/S	+3.27%	+47.96%	+112.84%	+96.58%	34.92B
CELLTRION, INC.	+1.22%	-1.44%	+14.57%	+46.95%	32.82B
INSMED INCORPORATED	+0.89%	+20.55%	-40.62%	+349.24%	24.7B
Average	-0.83%	+3.60%	+39.57%	+168.43%	39.44B
Weighted average by Cap.	+0.18%	+5.44%	+47.99%	+176.66%

	2026 *	2027 *
Net sales	-	-
Net income	-8.76M -7.85M -7.22M -6.54M -12.23M -832M -12.46M -86.11M -34.57M -438M -32.89M -32.19M -1.38B	-17.23M -15.43M -14.2M -12.86M -24.04M -1.64B -24.49M -169M -67.95M -861M -64.67M -63.29M -2.71B
Net Debt	-	-